更新于：2024-06-29
Tandospirone Citrate
枸橼酸坦度螺酮
更新于：2024-06-29
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C27H37N5O9 |
InChIKeyDMLGUJHNIWGCKM-DPFKZJTMSA-N |
CAS号112457-95-1 |
关联
35
项与 枸橼酸坦度螺酮 相关的临床试验枸橼酸坦度螺酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
枸橼酸坦度螺酮片在健康受试者中单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复空腹状态下的生物等效性试验
枸橼酸坦度螺酮片在健康受试者中单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复餐后状态下的生物等效性试验
100 项与 枸橼酸坦度螺酮 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸坦度螺酮 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸坦度螺酮 相关的专利（医药）
登录后查看更多信息
254
项与 枸橼酸坦度螺酮 相关的文献（医药）2024-01-24Emergency medicine international
Retracted: Clinical Analysis on the Effects of Tandospirone Citrate Assisted by Drawing Therapy on Medication Compliance and Sleep Quality in Patients with Anxiety Disorders
作者: International, Emergency Medicine
[This retracts the article DOI: 10.1155/2022/9295627.].
2023-12-01Schizophrenia research. Cognition
Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis
Article
作者: Yokoi, Yuma ; Wada, Ayumu ; Stickley, Andrew ; Sumiyoshi, Tomiki ; Yamada, Risa
Background:
In a previous meta-analysis, the use of serotonin1A(5-HT1A) receptor partial agonists of the azapirone class as an add-on therapy was associated with beneficial effects on positive symptoms and attention/processing speed in schizophrenia patients. This meta-analysis builds on that study by examining the effects of adjunctive treatment with 5-HT1A partial agonists in improving other domains of neurocognitive function in schizophrenia patients.
Methods:
A literature search was performed from 1987 to May 2023 to identify randomized controlled trials. The standardized mean difference (SMD) with 95 % confidence intervals (CI) was calculated when there were two or more studies. Four studies, involving 313 patients, met the inclusion criteria and were used in the analysis.
Results:
5-HT1A partial agonists (buspirone or tandospirone) did not have a significant effect on verbal learning (SMD = 0.08, 95 % CI = -0.31 to 0.47) or working memory (SMD = 0.15, 95 % CI = -0.09 to 0.39). Regarding executive functions (Wisconsin Card Sorting Test), positive but non-significant results were seen with the category number (SMD = 0.26, 95 % CI = -0.81 to 1.32), while non-significant effects were noted for percent preservation errors (SMD = -0.10, 95 % CI = -0.53 to 0.33).
Conclusions:
The absence of any significant benefits in the cognitive domains studied here may have been due to the variance in the concomitant medication (typical vs atypical antipsychotic drugs), the level of cognition at baseline, or other factors. Further studies with various types of 5-HT1A agonists are warranted to examine the potential cognitive efficacy of stimulating these receptors.
2023-12-01Journal of psychiatric research
Comparison of tandospirone and escitalopram as a symptomatic treatment in Multiple System Atrophy-cerebellar ataxia: An open-label, non-controlled, 4 weeks observational study
Article
作者: Gao, Jing ; Wang, Wei ; Quan, Meina ; Jia, Jianping ; Guo, Dongmei ; Xu, Shuo
BACKGROUND:
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure and motor dysfunction in parkinsonism and/or cerebellar ataxia. Patients with MSA usually present with depression and anxiety symptoms. This observational study of patients with MSA-cerebellar subtype (MSA-C) with subthreshold depression/anxiety symptoms aimed to compare the efficacy of escitalopram oxalate (an antidepressant drug) and tandospirone citrate (an anxiolytic drug).
METHODS:
Fifty-six MSA-C patients were included, with 28 patients in each treatment group. One group received escitalopram oxalate 10 mg/day and the other group received tandospirone citrate 30 mg/day. The patients were evaluated at baseline and after 4 weeks. Several psychiatric and neurological tests were performed, including the Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD), Scale for the Assessment and Rating of Ataxia (SARA), and the Scale for Outcomes in Parkinson's Disease for Autonomic Symptoms (SCOPA-AUT). Furthermore, post-void residual urine volume (PVR) and blood pressure were measured.
RESULTS:
There was a more substantial reduction in the HAMA/HAMD, scores of stance, finger tracking, and finger nose test in the SARA, and PVR in the tandospirone group. There was a more substantial reduction in scores of dysuria, light-headed when standing up, syncope and hyperhidrosis in the SCOPA-AUT in the escitalopram group (p's < 0.05).
CONCLUSIONS:
Tandospirone citrate was more effective in improving depression/anxiety and some cerebellar ataxia symptoms, whereas escitalopram was more effective in improving some autonomic symptoms in MSA-C patients over a short-term period in an open-label observational study without a control group. Further research is needed to evaluate the long-term effects of tandospirone and escitalopram in MSA-C in long-term placebo controlled trials.
30
项与 枸橼酸坦度螺酮 相关的新闻（医药）2024-06-03
·信狐药迅
申请上市临床申请生物类似药
2024-05-17
·米内网
上市批准申请上市临床申请核酸药物临床3期
2024-05-06
·信狐药迅
100 项与 枸橼酸坦度螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑 | 中国 | 2003-05-21 | |
| 神经症性障碍 | 日本 | 1996-07-10 | |
| 心理生理性障碍 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 地图样萎缩 | 临床3期 | - | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 274 | High-dose tandospirone (60 mg/d) | 膚夢製範醖簾膚壓壓獵(遞襯願衊範顧鏇鑰餘蓋) = 餘選鹽選構衊願鬱壓鏇 壓憲鹹網構鹹繭衊築襯 (獵鏇鑰積鬱糧鹹夢襯糧 ) 更多 | - | 2023-02-26 | ||
Low-dose tandospirone (30 mg/d) | 膚夢製範醖簾膚壓壓獵(遞襯願衊範顧鏇鑰餘蓋) = 築網鏇壓蓋壓夢淵襯製 壓憲鹹網構鹹繭衊築襯 (獵鏇鑰積鬱糧鹹夢襯糧 ) 更多 | ||||||
临床4期 | 274 | 60 mg/day tandospirone | 窪範構繭鬱範齋醖選餘(築構鑰襯淵製顧築齋窪) = 醖醖遞積積觸糧簾鹽憲 遞壓範壓簾蓋簾餘顧繭 (餘膚醖艱鑰繭醖壓鹽築 ) | - | 2022-08-01 | ||
30 mg/day tandospirone | 窪範構繭鬱範齋醖選餘(築構鑰襯淵製顧築齋窪) = 壓鑰繭繭築淵廠憲壓鑰 遞壓範壓簾蓋簾餘顧繭 (餘膚醖艱鑰繭醖壓鹽築 ) | ||||||
临床3期 | 772 | (AL-8309B 1.0%) | 蓋夢壓襯醖選艱積艱鏇(襯積觸觸繭願願壓獵鏇) = 顧遞鹹夢選顧鏇鬱範構 壓襯齋艱糧鬱醖構築醖 (繭鏇鹽蓋鑰顧製顧網製, 鏇鏇艱網範積顧鏇膚選 ~ 觸繭觸艱餘蓋積鹽顧選) 更多 | - | 2014-07-03 | ||
(AL-8309B 1.75%) | 蓋夢壓襯醖選艱積艱鏇(襯積觸觸繭願願壓獵鏇) = 遞繭製鹹觸鹹窪鬱觸積 壓襯齋艱糧鬱醖構築醖 (繭鏇鹽蓋鑰顧製顧網製, 鬱構鑰餘餘觸餘繭觸廠 ~ 築憲廠壓窪積淵鑰餘艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用